Meta-Analysis: NAD+ Supplementation Improves Metabolic Markers and Physical Function in Middle-Aged and Older Adults

NAD+ is one of those molecules that sounds too fundamental to be a good drug target—it's involved in hundreds of enzymatic reactions, from energy production to DNA repair to circadian rhythm regulation. But that ubiquity is precisely why it matters: NAD+ levels decline 50% between age 40 and 60, and that decline correlates with nearly every marker of metabolic aging. This meta-analysis, pooling data from 23 human trials, provides the first solid evidence that you can meaningfully restore NAD+ levels through supplementation, and that restoring those levels translates to better metabolic function and physical performance. The 42% increase in blood NAD+ isn't just a lab curiosity—it's paired with real-world improvements in insulin sensitivity (important for metabolic health and longevity), aerobic capacity (your ability to use oxygen efficiently), and muscle function. The fact that benefits took 8+ weeks to emerge tells you this isn't a stimulant effect; it's cellular remodeling. Your mitochondria are literally getting better at their job. For the 'I want to age slower' crowd, this is among the strongest evidence that supplementing a single molecule can move multiple aging biomarkers in the right direction simultaneously.

NAD+ (nicotinamide adenine dinucleotide) has been studied for over a century, but the link between NAD+ decline and aging only crystallized in the 2010s through work by David Sinclair, Charles Brenner, and others. Early excitement was tempered by uncertainty: Does oral supplementation actually raise NAD+ levels? Do higher levels translate to functional benefits? Are the effects meaningful in healthy humans or only in disease models? This meta-analysis addresses all three questions. First, yes—both NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) reliably increase blood NAD+ levels, with NMN showing slightly larger effects. Second, the increase translates to improved metabolic markers (insulin sensitivity, lipid profiles) and physical function (muscle endurance, aerobic capacity). Third, effects are present but smaller in healthy individuals; the biggest benefits show up in people with metabolic dysfunction or declining physical capacity—exactly the population where aging interventions matter most. The dose-response relationship suggests 500-1000mg daily is the sweet spot; lower doses show inconsistent effects. The heterogeneity across studies (I²=62%) largely reflects differences in baseline NAD+ status and supplementation duration. Notably, the safety profile is excellent—no liver toxicity, no cancer concerns, minimal side effects beyond occasional mild flushing. For longevity-focused supplementation, NAD+ precursors now have stronger human evidence than almost any other intervention.

Effects of nicotinamide riboside and nicotinamide mononucleotide supplementation on NAD+ metabolism: a systematic review and meta-analysis of human trials